A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis.

@article{Mollee2012API,
  title={A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis.},
  author={Peter N. Mollee and Campbell R Tiley and Ilona Cunningham and John Moore and H Miles Prince and Paul Cannell and Steve S Gibbons and Jillian Russyll Tate and Sanjoy Paul and Helen G Mar Fan and Devinder S Gill},
  journal={British journal of haematology},
  year={2012},
  volume={157 6},
  pages={766-9}
}
Thomas Prébet Steven D. Gore Sylvain Thépot Benjamin Esterni Bruno Quesnel Odile Beyne Rauzy François Dreyfus Claude Gardin Pierre Fenaux Norbert Vey Department of Hematologic malignancies, Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, USA, Departement d’Hematologie, Institut Paoli Calmettes, Marseille, Groupe Francophone des Myelodysplasies, Bobigny, E-mail: veyn@marseille.fnclcc.fr